Live feed08:45:00·86dPRReleasePDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCIPDSB· PDS Biotechnology CorporationHealth CareOriginal source
